CHMA - Chiasma posts positive data from late-stage MYCAPSSA study

Chiasma (CHMA) presented patient-reported outcomes ((PROs)) data from its late-stage trial in which patients with acromegaly reported significantly improved quality of life and work productivity after transitioning to the company's MYCAPSSA treatment.The patients showed improvements when transitioned from from long-acting injectable somatostatin analogs ((iSSAs)) to Chiasma's treatment.Shares up nearly 6% post market.In the MPOWERED study, 146 patients entered the 6-month run-in phase in which all patients received MYCAPSSA.It was a global, randomized, open-label and active-controlled, 15-month trial intended to support approval of MYCPASSA (oral octreotide capsules) in the European Union. Ninety-two patients who were responders to MYCAPSSA at end of run-in were then randomized into the 9-month randomized controlled treatment ((RCT)) phase to receive MYCAPSSA or iSSAs.Among the 92 randomized patients, results showed that several PROs, including quality of life and work productivity, were significantly improved at the end of the run-in phase compared to their results at the baseline of run-in (reflecting outcomes on

For further details see:

Chiasma posts positive data from late-stage MYCAPSSA study